Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors

Memorial Sloan Kettering cancer center, New York

University of Pittsburgh, Hillman Cancer Centre, Pittsburgh

Ircss Istituto Clinico Humanitas, Rozzano (MI)

Fondazione IRCCS Instituto Nazionale Dei Tumori, Milan

Virginia Commonwealth University, Richmond

Duke University Medical Center, Durham

Hospital Universitario Fundación Jiménez Díaz, Madrid

Mayo Clinic Jacksonville, Jacksonville

CHU de Bordeaux GH Sud Hôpital Haut Lévêque, Pessac

Sarah Cannon Research Institute, Nashville

Hospital Virgen Del Rocio, Seville

Ohio State University-Columbus, Columbus

University of Michigan Medical Center, Ann Arbor

Froedtert Hospital, Milwaukee

Minnesota Oncology Hematology, Minneapolis

Mayo Clinic Rochester, Rochester

University of Chicago, Chicago

Washington University, St Louis

Centre Léon Bérard, Lyon

Sarah Cannon Research Institute, Denver

University of Utah, Salt Lake City

City of Hope National Medical Center, Duarte

Stanford Hospital and Clinics, Stanford

Oregon Health and Science University, Portland

University of Iowa College of Medicine, Iowa City

Dana Farber Cancer Institute, Boston

Massachusetts General Hospital, Boston

University Of Texas Southwestern Medical Center, Dallas

University of Texas Southwestern Medical Center, Dallas

Fred Hutchinson Cancer Research, Seattle

Princess Margaret Cancer Centre, Toronto

CIUSSS de L'Est-De-Lile-De-Montreal, Montreal

The Netherlands Cancer Institute, Amsterdam

Hospital Santa Creu Y Sant Pau, Barcelona

Ico Duran y Reynals l'Hospitalet de Llobrega, Hospitalet de Llobregat, Barcelona

Royal Marsden Hospital, London

University College Hospital-London, London

Christie Hospital NHS Foundation Trust, Manchester